MARKET

PSTI

PSTI

Pluristem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.58
-0.56
-9.12%
Closed 19:32 03/03 EST
OPEN
6.25
PREV CLOSE
6.14
HIGH
6.25
LOW
5.55
VOLUME
626.37K
TURNOVER
--
52 WEEK HIGH
13.29
52 WEEK LOW
2.820
MARKET CAP
175.93M
P/E (TTM)
-3.5167
1D
5D
1M
3M
1Y
5Y
Stem Cell Market Trend Survey 2021 with Top Countries Data: Industry Insights by Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen | With Covid 19 Analysis
Mar 03, 2021 (The Expresswire) -- Global “Stem Cell Market” Report 2021 contains a comprehensive analysis of the important segments like market...
The Express Wire · 10h ago
Cathie Wood's ARK Invest Posts Fund Sales For Wednesday, Mar. 3, 2021: GOOGL, BMY, RHHBY, PSTI, TSM, TCEHY, NTDOY, ICE, BIDU, BEKE, DE, FLIR, NVDA, API
Alphabet (GOOGL) - 10,400 Shares  Bristol-Myers Squibb (BMY) - 198,865 Roche (RHHBY) - 515,538 Pluristem Therapeutics (PSTI) - 120 Taiwan Semiconductor Manufacturing (TSM) - 849,234 Tencent (TCEHY) -
Benzinga · 12h ago
ARK Invest's Cathie Wood To Appear On Benzinga's 'The Raz Report' Wednesday, Mar. 3, 2021 At 2 p.m. EST; Register Early For A Chance To Win To Ask Cathie A Question Live On Air
https://go.benzinga.com/webinar-registration1614549707198
Benzinga · 1d ago
Autologous Stem Cell Based Therapies Market Size 2021 with Top Countries Data, Trends, Share, Industry Growth, Supply and Manufacturers Analysis Research Report till 2027
Mar 01, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Autologous Stem Cell Based...
The Express Wire · 2d ago
Cathie Wood's ARK Invest Posts Fund Sales For Monday, Mar. 1, 2021: IBKR, MELI, RHHBY, PSTI, HIMS, BMY, SSYS, SPLK, SNAP, REGN, PINS, NVS, ICE, FLIR, HON, CRM, BABA, TCEHY, AAPL
Interactive Brokers (IBKR) - 113 Shares MercadoLibre (MELI) - 6,807 Roche (RHHBY) - 225,300 Pluristem Therapeutics (PSTI) - 14,036 Hims & Hers Health (HIMS) - 5,844 Bristol-Myers Squibb (BMY) -
Benzinga · 2d ago
Buerger's Disease Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Feb 25, 2021 (Market Insight Reports) -- The report for Buerger's Disease Treatment offers an assiduous analysis of contemporary market trends, driving...
Market Insight Reports · 02/25 11:38
Autologous Stem Cell Based Therapies Market Size, Share, Growth 2021, by Global Top Companies, Trends by Types and Application, Forecast to 2026
The Express Wire · 02/25 04:42
Stem Cell Market Size with Global Growth 2021: Top Countries Data with Business Sales Revenue, Opportunities, Industry Share, Drivers, and Risk Factor by Forecast Analysis 2024
Feb 24, 2021 (The Expresswire) -- Global “Stem Cell Market” trend report covers vital factors about the marketplace, profitability, competitive landscape...
The Express Wire · 02/24 07:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PSTI. Analyze the recent business situations of Pluristem through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PSTI stock price target is 9.00 with a high estimate of 10.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 88
Institutional Holdings: 5.39M
% Owned: 17.10%
Shares Outstanding: 31.53M
TypeInstitutionsShares
Increased
13
2.46M
New
25
-124.72K
Decreased
13
137.62K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Executive Director
Zalman Aberman
President/Chief Executive Officer/Director
Yaky Yanay
Chief Financial Officer/Treasurer/Secretary
Chen Franco-Yehuda
Lead Director/Independent Director
Doron Shorrer
Director
Rami Levy
Director
Maital Shemesh-Rasmussen
Independent Director
Isaac Braun
Independent Director
Issac Braun
Independent Director
Mark Germain
Independent Director
Moria Kwiat
No Data
About PSTI
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

Webull offers kinds of Pluristem Therapeutics Inc. stock information, including NASDAQ:PSTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PSTI stock methods without spending real money on the virtual paper trading platform.